An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change ...
Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.
Response rates to second-line STS therapies, including pazopanib, are typically <10% with median PFS <5 months, underscoring demand for predictive biomarkers. Transcriptomic profiling of 11 paired pre ...
The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...
Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
Coordinating early-phase immunotherapy trials across academic labs, industry sponsors, and clinical teams demands tight communication and cross-disciplinary teamwork, according to Bridget Keenan, MD, ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
Forecasted cost growth was highest in fully insured arrangements, consistent with constrained data rights; only about 60% felt able to audit full claims files. Employers with complete claims data ...
Effective October 13, 2026, federal financial participation is barred for specified pharmacologic and surgical interventions for Medicaid beneficiaries under 18 and CHIP enrollees under 19. CMS ...
Higher-performing Medicare accountable care organizations are smaller and characterized by real-time information sharing, ...
Obesity, MASH, and the Metabolic Dysfunction That Connects Them,' Jaime Almandoz, MD explores the following questions: As an endocrin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results